Icagen, Inc. (NASDAQ: ICGN) 31% LOWER; said following a planned meeting of the independent Data Monitoring Committee of the Company’s ASSERT trial of senicapoc (formerly ICA-17043) for the treatment of sickle cell disease in adults, the DMC recommended that the trial be terminated because of the low probability of achieving a reduction in crisis rate, the primary endpoint.
Among the available data, there were no statistically significant differences in safety measurements between the senicapoc and placebo treatment groups.
Pacer International, Inc. (Nasdaq: PACR) 9.4% LOWER; expects diluted earnings per share for 2007 to range between $1.50 and $1.60, versus the consensus of $1.99. The firm cited lower than forecasted revenue growth for the first quarter.
Pozen (Nasdaq: POZN) 8.7% HIGHER; Pozen and Glaxosmithkline plc (NYSE: GSK) said findings from two pivotal efficacy studies of more than 2,900 migraine sufferers demonstrated that Trexima(TM) provided superior headache relief at two hours and four hours compared to placebo, and two through 24-hour sustained pain-free results versus sumatriptan or naproxen monotherapy. The results were published today in the Journal of the American Medical Association (JAMA).
Oxford Industries Inc. (NYSE: OXM) 8.4% LOWER; reports Q3 EPS of $0.54, versus the consensus of $0.57. Revenues came in at $266.6 million versus the consensus of $270.74 million. Sees Q4 EPS of $1.00-$1.07, ex-gain, versus the consensus of $1.21. Sees Q4 sales of $285-$295 million, versus prior guidance of $295-$305 million and the consensus of $301.3 million.
Icagen, Inc. (NASDAQ: ICGN) 31% LOWER; said following a planned meeting of the independent Data Monitoring Committee of the Company’s ASSERT trial of senicapoc (formerly ICA-17043) for the treatment of sickle cell disease in adults, the DMC recommended that the trial be terminated because of the low probability of achieving a reduction in crisis rate, the primary endpoint.
Among the available data, there were no statistically significant differences in safety measurements between the senicapoc and placebo treatment groups.
Pacer International, Inc. (Nasdaq: PACR) 9.4% LOWER; expects diluted earnings per share for 2007 to range between $1.50 and $1.60, versus the consensus of $1.99. The firm cited lower than forecasted revenue growth for the first quarter.
Pozen (Nasdaq: POZN) 8.7% HIGHER; Pozen and Glaxosmithkline plc (NYSE: GSK) said findings from two pivotal efficacy studies of more than 2,900 migraine sufferers demonstrated that Trexima(TM) provided superior headache relief at two hours and four hours compared to placebo, and two through 24-hour sustained pain-free results versus sumatriptan or naproxen monotherapy. The results were published today in the Journal of the American Medical Association (JAMA).
Oxford Industries Inc. (NYSE: OXM) 8.4% LOWER; reports Q3 EPS of $0.54, versus the consensus of $0.57. Revenues came in at $266.6 million versus the consensus of $270.74 million. Sees Q4 EPS of $1.00-$1.07, ex-gain, versus the consensus of $1.21. Sees Q4 sales of $285-$295 million, versus prior guidance of $295-$305 million and the consensus of $301.3 million.
Top Gaining Stocks
Top Losing Stocks